Literature DB >> 11303062

Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment.

F I Tarazi1, K Zhang, R J Baldessarini.   

Abstract

Changes in members of the dopamine (DA) D(1)-like (D(1), D(5)) and D(2)-like (D(2), D(3), D(4)) receptor families in rat forebrain regions were compared by quantitative in vitro receptor autoradiography after prolonged treatment (28 days) with the atypical antipsychotics olanzapine, risperidone, and quetiapine. Olanzapine and risperidone, but not quetiapine, significantly increased D(2) binding in medial prefrontal cortex (MPC; 67% and 34%), caudate-putamen (CPu; average 42%, 25%), nucleus accumbens (NAc; 37%, 28%), and hippocampus (HIP; 53%, 30%). Olanzapine and risperidone, but not quetiapine, produced even greater up-regulation of D(4) receptors in CPu (61%, 37%), NAc (65%, 32%), and HIP (61%, 37%). D(1)-like and D(3) receptors in all regions were unaltered by any treatment, suggesting their minimal role in mediating actions of these antipsychotics. The findings support the hypothesis that antipsychotic effects of olanzapine and risperidone are partly mediated by D(2) receptors in MPC, NAc, or HIP, and perhaps D(4) receptors in CPu, NAc, or HIP, but not in cerebral cortex. Selective up-regulation of D(2) receptors by olanzapine and risperidone in CPu may reflect their ability to induce some extrapyramidal effects. Inability of quetiapine to alter DA receptors suggests that nondopaminergic mechanisms contribute to its antipsychotic effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303062

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

1.  Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.

Authors:  F I Tarazi
Journal:  J Sci Res Med Sci       Date:  2001-10

2.  Effects of risperidone on dopamine receptor subtypes in developing rat brain.

Authors:  Taylor Moran-Gates; Christopher Grady; Young Shik Park; Ross J Baldessarini; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2006-12-18       Impact factor: 4.600

3.  Brain differences in first-episode schizophrenia treated with quetiapine: a deformation-based morphometric study.

Authors:  Chunlan Yang; Shuicai Wu; Wangsheng Lu; Yanping Bai; Hongjian Gao
Journal:  Psychopharmacology (Berl)       Date:  2014-08-02       Impact factor: 4.530

4.  In a Model of Neuroinflammation Designed to Mimic Delirium, Quetiapine Reduces Cortisol Secretion and Preserves Reversal Learning in the Attentional Set Shifting Task.

Authors:  Zyad J Carr; Lauren Miller; Victor Ruiz-Velasco; Allen R Kunselman; Kunal Karamchandani
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-22       Impact factor: 4.147

Review 5.  Lurasidone: a new treatment option for bipolar depression-a review.

Authors:  Radhika Bawa; Jonathan R Scarff
Journal:  Innov Clin Neurosci       Date:  2015 Jan-Feb

6.  In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia.

Authors:  Laura C Amann; Michael J Gandal; Robert Lin; Yuling Liang; Steven J Siegel
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

7.  Differential regional and dose-related effects of asenapine on dopamine receptor subtypes.

Authors:  Frank I Tarazi; Taylor Moran-Gates; Erik H F Wong; Brian Henry; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2008-02-24       Impact factor: 4.530

8.  Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.

Authors:  Monika Vinish; Ahmed Elnabawi; Jean A Milstein; Jesse S Burke; Jonathan K Kallevang; Kevin C Turek; Carien S Lansink; Istvan Merchenthaler; Aileen M Bailey; Bryan Kolb; Joseph F Cheer; Douglas O Frost
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-25       Impact factor: 5.176

9.  Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia.

Authors:  Yong Kee Choi; Shikha Snigdha; Mohammed Shahid; Jo C Neill; Frank I Tarazi
Journal:  J Mol Neurosci       Date:  2009-05-20       Impact factor: 3.444

10.  Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.

Authors:  Vance L Albaugh; Cathy R Henry; Nicholas T Bello; Andras Hajnal; Susan L Lynch; Beth Halle; Christopher J Lynch
Journal:  Obesity (Silver Spring)       Date:  2006-01       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.